|XTend Medical Set to Redefine Cancer Detection With Nanotechnology|
|By Michael Vlaicu|
|Tuesday, 20 October 2009 08:35|
Cancer has quickly become one of the deadliest diseases, causing well over 13% of all human deaths. Cancer rates could further increase by 50% to 15 million new cases in the year 2020, according to the World Cancer Report, the most comprehensive global examination of the disease to date. Due to this emerging need for cancer detection medical devices, new and innovative technologies are bound to step foot within the coming years, in what could potentially be one of the biggest markets of our era.
Xtend Medical (PINK:XMDC) is set to partner up with BioHarp Korea, a division of Uni Bio-Tech, Inc, a Seoul, Korea based developer and manufacturer of medical imaging devices. Under the terms of the merger, BioHarp Korea will transfer all patents, software, assets, and proprietary information relating to the BioHarp Nano Sensor imaging device. Upon completion of the merger, the combined company will apply for a name change from XTend Medical to BioHarp Uni, US, and will effectuate a new trading symbol and cusip number.
The merger is expected to be completed 30 to 60 days post the October 1st, 2009 press release. BioHarp is a cutting-edge medical imaging device that utilizes a non-invasive approach to detect inflammation in the human body on a cellular level. It is an hand-held, lightweight, portable, and affordable device which has tested for 100% no-false positives, and 95.9% cancer positive .
With the U.S. National Science Foundation predicting that the market for nanotechnology, or products containing nanotechnology, will reach $1 trillion in 10 to 15 years -- XTend, and other medical nanotechnology devices should begin to receive a lot more praise, including the likes of NASA, which has already developed a nanotechnology-based biosensor which helps detect biohazards.
"If we realize our sales and marketing goals and hit our projected revenues based on the current inquiries we've received, the company's market cap will be substantial," stated Mr. Paul D. Lisenby, CEO of XTend Medical.
About XTend Medical
XTend Medical is a company that specializes in the manufacturing and distribution of the latest in telemedicine and telehealth solutions for the healthcare industry. Their dedication to insuring the products and services offered to healthcare organizations, third-world countries, and physician groups are at the forefront of medical technology. Their continued efforts in identifying global companies with true product potential in the healthcare industry puts them in an advantageous position to capitalize on a global basis.
The software used in the BioHarp device is a Windows based, 3D imaging program that directs the users to specific points in the body for examination. As you can see from the following slides, this software pinpoints the readings from the BioHarp and gives the physician or tech a full reading for further treatment of the areas scanned. The software incorporates the details needed for the proper sales functions to major healthcare companies. By requesting specific patient data as well as any corresponding medical record numbers, the integration into the databases for internal EHR (Electronic Health Records) that current healthcare companies are embracing for patient care.
*Click image to enlarge
The unit itself combines with state-of-the-art software developed specifically to assimilate and deliver the results from the 1 or 5-sensor “wand” that scans the body and sends the data for review by a licensed physician, physician’s assistant, or registered nurse for possible further testing or to define the proper course of treatment. Unlike CT Scans, MRI’s and other similar testing devices, the BioHarp penetrates to the cellular level to detect inflammation differences in the cells. The resulting scan of the body can detect early disease states such as diabetes, liver damage, and other organ problems that, when treated at this early stage, can assist managed care companies, physicians, and insurance companies in lowering health costs significantly.
The U.S. National Science Foundation has predicted that the market for nanotechnology, or products containing nanotechnology, will reach $1 trillion in 10 to 15 years. Rising medical costs, demands for less-invasive procedures and pressures for immediate feedback of medical conditions, all point to nanotechnology as offering a new approach in healthcare.
Clinical Trial Results
A total of 656 measurements were carried out for three weeks on mice including those whose subcutaneous tissue was transplanted with cancer cells. In the initial seven (7) days after the transplantation, correct were 166 out of 190 measurements (87.4%), in which normal, healthy mice were not diagnosed with cancer.
The total results were 629 hits out of 656 measurements (95.9%) in the experiment period, in which normal, healthy mice were not diagnosed with cancer. It can be appreciated that the diagnostic device of the invention has excellent sensitivity to biological electro-magnetic signals caused by cancer. In another experimental example of the invention, the diagnostic device of the invention was used to diagnose cancer in the mice whose abdominal cavity was transplanted with leukemia cells.
As a result, 84.7% were diagnosed with cancer in a control group, and the remaining 15.3% were diagnosed with inflammation instead of cancer. In the mice whose abdominal cavity was transplanted with leukemia cells, 93.1% were diagnosed with cancer. In view of the fact that cancer will not be induced in the control group but the group transplanted with cancer has a high probability of cancer, it can be appreciated that the diagnostic device of the invention has excellent sensitivity to biological electro-magnetic signals caused by cancer. Clinical data source here
Moreover, on August 15-17, 2007, BioHarp made its debut at FIME 2007 The world's medical marketplace, in Miami Beach convention center. Over 150 attendees, including 32 certified MD's from across the world, were scanned and diagnosed with BioHarp. The product demonstration included a 5 minutes scan of the major organs. In every case, where the volunteer had knowledge of their own medical history, we were able to confirm BioHarp's readings with 100% success. In other cases, we may identified potential problem areas, the volunteer should have checked out. There was a great deal of buzz at the UnI-Biotech booth, with several attendees returning with their co-workers, friends, and partners.
Extended Potential Target Markets
In addition to the human markets, the BioHarp will be marketed to the pet and equine industries. The management at XTend has made several contacts with the veterinary market to utilize the BioHarp to scan dogs, cats, and other pets in order to discover potential harmful conditions that can be treated through nutrition and medications. The ability for the veterinarian to market this as an added service allows them to create an additional revenue stream as well as giving pet owners the ability to monitor their pet's health and hopefully alleviate costly procedures. The equine industry itself can be very lucrative for the company in the future.
The management at XTend has several thoroughbred trainers and owners they have spoken with about utilizing the BioHarp as part of a daily routine for racehorses to insure their training and subsequent earnings potential is not compromised. As the BioHarp unit can be deployed to the stables, part of their post exercise routine would be for the trainer or vet to scan the horse upon completion of their workout or race and determine if there is any underlying inflammation that can lead to being sidelined, thereby eliminating the ability to earn money racing. This market alone is global in nature as there are literally hundreds of racetracks with thousands of horses, each representing a significant investment to their owners. The yearling sales at places like Keenland, wherein owners plunk down millions to own a potential Triple Crown winner, would benefit by having a BioHarp scanner available in order to scan potential champions to insure the fitness of the horse and to detect potential problems that could arise in the future.
These scans would be done with the one sensor unit and would probably be sold and managed by our internal medical team at BioHarp UNI US. The potential trainers and owners would contract with us to scan the animals regularly; generating daily, weekly, and/or a monthly maintenance fee schedule for the company. See source here
he revenue model for the BioHarp comes from both the hardware and software sales. The single sensor unit will sell for $5,000 US dollars and the five sensor unit will be $30,000. The software will be sold on a license agreement wherein BioHarp UNI US will charge $19.99 per month per patient license, thereby creating a continued revenue stream once the unit hardware is sold. Naturally, if we have groups that are purchasing thousands of units, we will have a discount structure to these monthly fees. With the patient potential in the millions, our revenue model will be very strong and consistent for years to come. See source here
*Click image to enlarge
1) BioHarp Software Patent: Link to patent here United States Patent Application 20090137895 Real-time diagnostic system employing non-invasive method to analyze electro-magnetic field radiated from a subject and the variation thereof 2) Hardware Sensor Pattern: Link to patent here USPTO Patent Application 20090182218 Sensor for detecting biological electro-magnetic signal and the diagnostic device using the same. Experienced Management Team Sam Lee Mr. Lee is the brainchild behind the BioHarp unit. Mr. Lee has spent the past 14 years perfecting the nano bio-sensor technology and has worked diligently in the continued development of the sensor units and overall BioHarp product. Mr. Lee holds a BA in Public Administration and has a MA in Animal Physiology and Biochemistry. Achievement - Established ‘ UNI BIO-TECH.,INC. ’, Seoul Korea. Jun 19. 2000. - Established R&D Biological Signal Technology, Calif. U.S.A. Mar 1989. - R&D Biological Signals - Analysing Study of the Characteristics of revolutionary Bio-Substances - Unigue prosessing of Bio-Materials for Nano-Biosensor - Nano- Biosensor development and Production for Hand-Held Detector. - R & D of Immune strengthening, Prevention and Treatment of Cancer & related Diseases. - Ubiquitous, e-Healthcare, Monitoring System Development - Early stage disease detector using Nano-Biosensor - Detection of Biological Signals Non-Invasive, Non-Restrictive Diagnostic method - New Model Development of prototype, Sep 2008 ~ Jun 2009 - KIMES 2008 participated in International Medical Convention at Seoul Korea, Mar 15. ~ Mar 17. 2008 - FIME 2007 participated in International Medical Convention at Miami U.S.A, Aug 15. ~ Aug 17. 2007 - Development of Biological signals detection device- BIOHARP-Hand held device, Jan 2007 ~ Aug 2007 - KGLP approved laboratory animal pre-clinical experiment For new device which detects of early stage various diseases, Apr 2004 ~ May 2004 - Development of Prototype : Biological signals device of single Sensor and Multi-Sensor’s, Apr 2002 ~ May 2004 * For more information on the CEO, CFO, President and Staff behind BioHarp, visit the company's website here.
Since the beginning of October, volume for XMDC has been on the rise and experiencing over 900% increases in daily volume! The monthly volume has jumped almost 600% and October isn’t over yet.
This indicates an enormous interest in this company and its activities as of late. In response, the price action has started a bullish trend with impressive gains. This comes after spending close to 16 months in the bottom half of a very well-defined price channel. If you’re looking to finally get in at the beginning of a price run, this could be the stock! The key indication, along with the jump in volume (grey bars on the chart), is the price has been testing the top of that long established price channel at .02 cents (red circle on the chart).
Today was actually the third time the price had tested that top trend-line this month. It has been observed numerous times in Technical Analysis that the third time is the charm and usually the price will break the trend-line, turn it into support, and will stay above it. As predicted, the charm worked and the price broke through the .02 cent line and closed well above it today.
This move shows the price channel has expanded (Blue lines on the chart). Typically, one doubles the height of the previous channel and this indicates the old top trend-line (dashed Blue line on the chart) is now the new mid-line. This shifts the top trend-line up to the .04 cent level. More evidence that this new price channel is now in control is that the price actually closed right at the ¾ trend-line today at .03 cents. All this positive sentiment is backed by the standard bullish signal of the daily 100 SMA (Orange line) moving above the daily 200 SMA (Yellow line).
The bullish signal is further strengthened by both these moving averages currently trending up. It’s good to keep in the back of your mind that during the month of October 2007, the price of this stock was trading at levels above .10 cents and actually reached up to .39 cents. That would be a 1200% gain from today’s closing price.
With cancer rates set to increase by 50% to 15 million new cases in 2020, the early detection cancer medical device industry could potentially become one of the largest potential markets of our era. XTend Medical has taken a new approach to solving the need by making a device which is lightweight, portable, affordable, and highly accurate and effective. The BioHarp product tested tested for 100% no-false positives, and 95.9% cancer positive, which in its own right is something to marvel at, without even considering the other variables. The single sensor unit will sell for $5,000 US dollars and the five sensor unit will be $30,000. The software will be sold on a license agreement wherein BioHarp UNI US will charge $19.99 per month per patient license, thereby creating a continued revenue stream once the unit hardware is sold. With the CEO admitting himself that the current market cap of $18M is highly undervalued at these levels, an investment in XTend Medical should seem like a no-brainer.
Disclosure: Long XMDC
———–By reading MiV Investments Inc. company profiles you agree to the disclaimer, and thereby will not hold Michael Vlaicu accountable for any transactions or decisions you make. It is up to you to do your own due diligence. MiV Investments Inc. is not paid, compensated or in any way incentivized to report news and developments about publicly traded companies, unless otherwise stated.